Skip to main content
. Author manuscript; available in PMC: 2016 Jan 15.
Published in final edited form as: Clin Cancer Res. 2014 Nov 25;21(2):303–311. doi: 10.1158/1078-0432.CCR-14-1781

Table 2. Number of patients experiencing adverse events by dose group.

Dose
10 mg MMC/Half BCG (n=3) 10 mg MMC/Full BCG (n=3) 20 mg MMC/Full BCG (n=3) 40 mg MMC/Full BCG (n=3)
Adverse Event Grade* 1 2 3 1 2 3 1 2 3 1 2 3
Chills 1 0 0 1 0 0 3 0 0 2 0 0
Fatigue 3 0 0 2 0 0 2 1 0 1 1 0
Fever 1 0 0 1 0 0 2 0 0 2 0 0
Hematuria 2 0 0 2 1 0 3 0 0 2 1 0
Non-infectious cystitis 2 1 0 2 1 0 2 0 0 1 2 0
Bacterial cystitis 1 0 0 1 0 0 0 0 0 0 0 1
*

Grading according to CTCAE v4.0.